Breaking Finance News

Victrex PLC (LON:VCT) price target held steady at 1,900.00GBX, issued a ratings update today by Peel Hunt

Victrex PLC (LON:VCT) had its price target hold steady to 1,900.00GBX by Peel Hunt in an issued report announced 10/11/2016. The latest stock price target implies a potential upside of 0.06% based on the company's most recent close.

On 10/05/2016, Exane BNP Paribas reported on Victrex PLC (LON:VCT) held steady the target price at 1,450.00GBX that suggested an upside of 0%.

Showing a price of 1,791.00GBX, Victrex PLC (LON:VCT) traded 9.06% higher on the day. With the last stock price close up 16.79% from the 200-day average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. VCT has recorded a 50-day average of 1,551.44GBX and a two hundred day average of 1,514.64GBX. Trading volume was up over the average, with 281,190 shares of VCT changing hands over the typical 254,984

Performance Chart

Victrex PLC (LON:VCT)

Victrex PLC has a price-earnings ratio of 18.88 with a one year low of 1,275.58GBX and a one year high of 1,961.00GBX VCT’s total market value is presently 0 GBX.

Also covering Victrex PLC's target, a total of 15 equity analysts have released a report on Victrex PLC. The 12-month price target is 1,716.00GBX with 4 brokers rating the stock a strong buy, 2 firms rating the stock a buy, 9 firms rating the stock a hold, 1 equity analyst rating the company a underperform, and lastly 0 brokerages rating the stock a sell.

General Company Details For Victrex PLC (LON:VCT)

Victrex plc is a United Kingdom-based holding company. The Company is engaged in the manufacture and sale of high performance polymers. The Company's operating segments are Victrex Polymer Solutions and Invibio Biomaterial Solutions. The Victrex Polymer Solutions segment focuses on its automotive, aerospace, electronics and energy markets. The Invibio Biomaterial Solutions segment focuses on providing specialist solutions for medical device manufacturers. It offers its services to over 15,000 aircrafts in approximately 40 countries across the world. The Company intends to focus on polyaryletherketones (PAEK) in automotive, aerospace, electronics and energy, downstream integration opportunities and extending into other markets. It also focuses on spine, trauma, dental and orthopedics, delivering solutions based on polyetheretherketone (PEEK) and other enabling polymers. The Company's subsidiaries include Victrex Manufacturing Limited, Invibio Limited and Victrex Trading Limited.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *